T he first decade of optogenetics has seen many efforts to improve our understanding of normal and pathological neural circuitry ( 1) . The great impact of these efforts has stemmed from an alliance between systems neuroscientists and protein engineers-the fi rst group identifying neural circuits amenable to causal dissection, the second developing tools that enable unprecedented degrees of control over neural activity. The next decade of optogenetics is likely to see the development of a new alliance that may have similarly important implicationsone between optogenetics and translational medicine. On page 94 of this issue, Bryson et al. describe one model for how such an alliance may proceed, applying tools from optogenetics in concert with ideas in regenerative medicine to restore muscle function in a mouse model of peripheral nerve injury ( 2) .
The threshold question that all optogenetic experiments face is that of achieving stable expression of opsins in the desired cell population ( 1). Bryson et al. adopted an approach to solve this problem that has some precedent in the fi eld ( 3) . The authors genetically engineered mouse embryonic stem cells to stably express channelrhodopsin-2 (ChR2), a cation channel sensitive to blue light, and then differentiated these cells in vitro to obtain optogenetically activatable ChR2 motorneurons. Thus, shining blue light on these ChR2 motorneurons could robustly drive neuronal fi ring. They then grafted aggregates of stem cells (embryoid bodies) containing these ChR2 motorneurons into a mouse model of muscle denervation in which the sciatic nerve was ligated. The engrafted ChR2 motorneurons survived, matured, and grew to innervate the denervated muscles of the lower limb, allowing Bryson et al. to restore muscle function through illumination of the graft site in anesthetized mice with blue light.
For reasons that remain somewhat unclear but are the subject of active study through computational modeling ( 4) , optogenetic stimulation of ChR2 motorneurons results in motor unit recruitment patterns that closely track physiological motor unit recruitment order ( 5), unlike electrical stimulation, which produces a reverse or random recruitment order ( 6) . Bryson et al. were therefore able to use their engrafted ChR2 motorneurons to achieve "orderly recruitment" of reinnervated muscles. These results confi rm previous reports indicating that optogenetic stimulation activates muscles in a way that induces less fatigue than electrical stimulation, thus enabling optogenetically induced force to be sustained for long durations through preferential recruitment of fatigueresistant motor units ( 5) .
The capabilities that Bryson et al. demonstrate are likely to spur many subsequent studies. One critical question is whether the restoration of muscle function achieved can be extended to mice that are not under anesthesia. This will likely require the use of chronically implantable light-emitting nerve cuffs, which allow for optogenetic activation of peripheral nerves in freely moving animals. ( 7) . Also of great interest will be the quality and persistence of the enabled control. Bryson et al. describe ChR2 motorneuron endplates (innervated regions of muscle) that are malformed, and hypothesize that this is due to initial in vivo inactivity of the transplanted ChR2 motorneurons. Chronic cuff implantation would allow for optogenetic activation of these neurons immediately after engraftment, which may help prevent such malformation. The long-term survival of engrafted ChR2 motorneurons is another major challenge that must be overcome.
The cell transplantation framework used by Bryson et al. may also have applicability in the treatment of other forms of nervous pathology. Stem cell grafts and electrochemical neuroprostheses may have potential use in the treatment of spinal cord injury ( 8, 9) . Combining these strategies with the stimulation specifi city provided by the optogenetic approach of Bryson et al. may be a productive direction for future research efforts.
By demonstrating how results from regenerative medicine may be integrated with new techniques in muscle physiology to restore function, Bryson et al. exemplify the type of interdisciplinary synthesis that will be essential for developing translational optogenetics. Like Bryson et al., others have identifi ed neurons outside the brain as the likely fi rst target for optogenetic translation ( 10) . In addition to control over peripheral motorneurons ( 2, 5, 7) , foundational work has been done in this area to demonstrate that optogenetics may be used to control retinal cells ( 11) and pain circuits ( 12, 13) . The fl eeting stability of the cyanoformate ion formed from CO 2 and cyanide has implications for plant enzymology and CO 2 sequestration.
I n the ever-expanding universe of compounds prepared to date, it is remarkable that a two-carbon ion with an apparently simple electronic structure could have eluded structural characterization until now. It is especially notable because this ion is formed from carbon dioxide (CO 2 ) and cyanide (CN -), each with a rich chemical history. On page 75 of this issue, Murphy et al. ( 1) report trapping the elusive cyanoformate ion as a crystalline salt with a bulky and unreactive cation. Their crystallographic and spectroscopic analysis along with quantum-mechanical calculations reveal a seemingly ordinary carbon-carbon (C-C) bond with the length of ~1.5 Å, yet cyanoformate balances on the brink of fragmentation in nonpolar environments and its C-C bond breaks in more polar solvents.
On fi rst glance, bonding of CO 2 and CN -could be expected because the carbon atom in CN -is nucleophilic (electron rich), whereas the carbon in CO 2 is electrophilic (electron poor) (see the fi gure, panel A). Every discussion on the chemistry of ketones, esters, and similar functional groups in an undergraduate organic chemistry class includes attack of the lone pair of electrons of a nucleophile at the carbonyl (the C=O group). In this process, a π bond is sacrifi ced to give a σ bond. Usually, σ bonds are stronger than π bonds, so the overall transformation is thermodynamically favorable. For example, interaction of cyanide with ketones and aldehydes (formation of cyano alcohols, also known as cyanohydrins) dates back to the classic 1850 work of Strecker (see the fi gure, panel B) ( 2) .
Formation and decomposition of cyanonohydrins is commonly used by bacteria, plants, fungi, and a few animals (e.g., millipedes) as a way to store cyanide and release it on demand (cyanogenesis) ( 3) . Rumor has it that this reaction offered protection from cyanide to Grigori Rasputin, a controversial fi gure of Russian history ( 4) . One attempt to poison Rasputin failed because of his apparent immunity to cyanide. The theory is that his killers put the cyanides in sweet pastries, and the carbonyl functionality on the sugar molecules served as an antidote by reacting with the cyanide and forming cyanohydrins.
However, CO 2 is a much tougher nut to crack than a typical ketone, and its reaction with cyanide is considerably less favorable. Not only is the energy cost for distorting the linear CO 2 molecule into the bent sp 2 geometry (~75 kcal/mol) ( 5) comparable to the C-C bond energy, but π bonds at sphybridized carbons are stronger than π bonds at sp 2 -hybridized carbons ( 6, 7) . The relatively small enthalpic preference for cyanoformate formation is wiped out by unfavorable entropy. The 133° O-C-O angle in cyanoformate suggests that CO 2 is poised, like a spring, for the escape to its relaxed linear geometry. The ephemeral nature of cyanoformate illustrates that C-C bonds can, under 
O - However, several challenges remain to be overcome before the fi rst successful optogenetic therapy is realized. Among these is the extension of optogenetic techniques beyond murine models to nonhuman primates ( 14) , particularly in neural circuits outside the brain. Equivalently important is improved assessment of the long-term safety of opsin expression across a variety of delivery strategies, including both viral vectors (such as adeno-associated viruses), and cell transplants such as those used by Bryson et al. The development of robust light-emitting devices that are well tolerated upon implantation is also critical; these may potentially be wirelessly powered. And opsins will need to be developed that exhibit improved light sensitivity (particularly to red light) and a wide range of different temporal characteristics. These challenges notwithstanding, this study by Bryson et al. provides an elegant step along the path to optogenetic translation (see the fi gure).
